findmyKOL

Edwin Ryan, MD

Basic profile

Ophthalmology

ORCID↗NPI↗
✓ Full record
RegionMinneapolis, MN · MidwestSpecialtyOphthalmologyFocusOphthalmology
Active KOLfindmyKOL type: RegionalLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Edwin Ryan is an Ophthalmology physician. OpenAlex indexes 91 publications with 2,288 citations (h-index 25).

Overview

Scholarship

indexed output and impact (OpenAlex)
91publications

Distinct works indexed by OpenAlex, matched via ORCID.

2,288citations

Total citations across indexed works.

25h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
5companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

7760 France Ave S
Suite 310
Minneapolis, MN 554355800

Telephone

952-929-1131

Registry record last updated 8 Nov 2010.

View the NPPES registry record

Industry payments

5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Sensory organs

    88.9%
    Antineovascularisation agents84%
    Faricimab-svoa100%
    Part B, office-administered≥35 patients
    Vascular Endothelial Growth Factor Inhibitor3%
    Ranibizumab100%
    Part B, office-administered≥13 patients

    + 6 more classes in this area

  • Cancer & immunology

    10.3%
    Vascular Endothelial Growth Factor Inhibitor10.3%
    Aflibercept95%Bevacizumab5%
    Part B, office-administered≥120 patients
  • Musculoskeletal

    0.4%
    Cyclooxygenase Inhibitor0.4%
    Ketorolac Tromethamine100%
    Part D≥21 patients
Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”